Treatment of cataracts and other ophthalmic diseases
CA 2484512 C · Owner: Colby Pharmaceutical Company · Inventors: Matier, William L.; Patil, Ghanshyam
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Opthalmically acceptable compositions used in arresting the development of cataracts or macular degeneration comprising a pharmaceutically acceptable carrier or diluent and a compound having the formula: Where R1 and R2are independently, H or C1 to C3 alkyl; R3 and R4 are independently C1 to C3 , alkyl; and where R1 and R2 taken together, or R3 and R4, taken together or , both may be cycloalkyl; R5 is H, OH or C1 to C6 alkyl; R6is or C1 to C6 , alkyl alkenyl, alkynyl, or substituted alkyl or alkenyl; R7 is C1 to C6 alkyl, alkenyl, alkynyl, or substituted alkyl or alkenyl or where R6 and R7 or R5, R6 and R7, taken together, form a carbocycle or heterocycle having from 3 to 7 atoms in the …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 19, 2003 and granted April 16, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended May 19, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 19, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.